ArticleBlood research2026
Nuanced treatment decision in newly diagnosed multiple myeloma patients aged 65-75 years: a real-world study.
Article in Blood research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe optimal treatment strategy for patients aged 65-75 years with multiple myeloma (MM) remains undefined, as most clinical trials involving transplant-eligible patients have excluded this subgroup. We investigated the real-world treatment patterns, outcomes, and clinical impact of autologous stem cell transplantation (ASCT) and quadruplet therapy in this population.
methodsWe retrospectively analyzed 561 patients aged 65-75 years with newly diagnosed MM treated between 2015 and 2023 at two tertiary centers. Patients were stratified by age (< 70 vs. ≥ 70 years) and ASCT status.
resultsThe use of quadruplet regimens and ASCT has increased markedly since 2021. Among patients aged 65-69 years, ASCT was associated with improved progression-free survival (PFS) (hazard ratio [HR], 0.37; 95% confidence interval [CI], 0.27-0.53; P < 0.001) and overall survival (HR, 0.30; 95% CI, 0.17-0.55; P < 0.001). In those aged 70-75 years, quadruplet therapy was independently associated with superior PFS (HR, 0.29; 95% CI, 0.12-0.73; P = 0.009). Similarly, in non-transplant recipients, quadruplet therapy remained a favorable predictor of PFS (HR, 0.40; 95% CI, 0.19-0.87; P = 0.021).
conclusionIntensive treatment strategies-including ASCT and quadruplet therapy-are both feasible and beneficial for selected patients with MM aged ≥ 65 years. Therefore, chronological age alone should not be used to determine treatment eligibility. These findings provide real-world evidence that supports a shift toward individualized fitness-based treatment approaches to optimize outcomes in older patients with MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.